KRAS and leukemia: Our findings suggest that SOS1 PROTACs may potentially serve as a valuable option for exploring the biological functions of SOS1 and as a basis for developing novel antitumor drugs targeting KRAS-mutant cancers and BCR–ABL–driven leukemia.